1 Min Read
Sept 4 (Reuters) - FARON PHARMACEUTICALS OY:
* U.S. FDA PROPOSES PROCEEDING DIRECTLY TO BLA SUBMISSION FOR TRAUMAKINE ® FOLLOWING COMPLETION OF EUROPEAN AND JAPANESE PHASE III STUDIES Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.